118 related articles for article (PubMed ID: 32949443)
1. Additional comments regarding IGH studies in multiple myeloma.
Smith SC; Althof PA; Dave BJ; Sanmann JN
Genes Chromosomes Cancer; 2021 Jan; 60(1):55. PubMed ID: 32949443
[No Abstract] [Full Text] [Related]
2. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH.
Boersma-Vreugdenhil GR; Peeters T; Bast BJ; Lokhorst HM
Blood; 2003 Feb; 101(4):1653. PubMed ID: 12560243
[No Abstract] [Full Text] [Related]
3. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding.
Ravindran A; Greipp PT; Wongchaowart N; Smadbeck JB; Peterson JF; Ketterling RP; Kumar SK; Baughn LB
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e710-e713. PubMed ID: 34172422
[No Abstract] [Full Text] [Related]
4. [A preliminary study on translocation of the immunoglobulin heavy chain gene in KM3 myeloma cell line].
Shen H; Hou J; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):533-5. PubMed ID: 11769679
[TBL] [Abstract][Full Text] [Related]
5. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
6. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
8. Comparison of IGH Profile Signals Using t(4;14) and IGH Break-Apart Probes by FISH in Multiple Myeloma.
Smol T; Daudignon A
Cytogenet Genome Res; 2017; 153(1):18-21. PubMed ID: 29040969
[TBL] [Abstract][Full Text] [Related]
9. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.
Magrangeas F; Cormier ML; Descamps G; Gouy N; Lodé L; Mellerin MP; Harousseau JL; Bataille R; Minvielle S; Avet-Loiseau H
Blood; 2004 May; 103(10):3869-75. PubMed ID: 14715636
[TBL] [Abstract][Full Text] [Related]
10. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Bergsagel PL; Chesi M; Nardini E; Brents LA; Kirby SL; Kuehl WM
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13931-6. PubMed ID: 8943038
[TBL] [Abstract][Full Text] [Related]
11. [Subclassification of multiple myeloma based on the partner genes of immunoglobulin heavy chain gene translocations].
Nishida K; Taniwaki M
Rinsho Ketsueki; 2000 May; 41(5):414-7. PubMed ID: 10879102
[No Abstract] [Full Text] [Related]
12. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
13. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
[TBL] [Abstract][Full Text] [Related]
14. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
[TBL] [Abstract][Full Text] [Related]
15. [Study of the etiologic pathogenesis of multiple myeloma].
Hou J; Kong X
Zhonghua Xue Ye Xue Za Zhi; 1998 Nov; 19(11):607-9. PubMed ID: 11263345
[No Abstract] [Full Text] [Related]
16. Multiethnic myeloma.
Weiss BM
Blood; 2013 Apr; 121(16):3062-4. PubMed ID: 23599258
[No Abstract] [Full Text] [Related]
17. Promiscuity of translocation partners in multiple myeloma.
Martin LD; Belch AR; Pilarski LM
J Cell Biochem; 2010 Apr; 109(6):1085-94. PubMed ID: 20127714
[TBL] [Abstract][Full Text] [Related]
18. [Transition to aggressive phase in a multiple myeloma patient with IgH/CCND1 translocation and diffuse osteosclerotic lesions].
Hatsuse M; Fuchida S; Okano A; Murakami S; Shimazaki C
Rinsho Ketsueki; 2016 Apr; 57(4):483-8. PubMed ID: 27169455
[TBL] [Abstract][Full Text] [Related]
19. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.
Bergsagel PL; Nardini E; Brents L; Chesi M; Kuehl WM
Curr Top Microbiol Immunol; 1997; 224():283-7. PubMed ID: 9308253
[TBL] [Abstract][Full Text] [Related]
20. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
